Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

T6394

Sigma-Aldrich

Timolol maleate salt

≥98% (TLC), powder

Synonyma:

S-(−)-1-(t-Butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate salt, Timolol hydrogen maleate

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen


About This Item

Empirický vzorec (Hillův zápis):
C13H24N4O3S · C4H4O4
Číslo CAS:
Molekulová hmotnost:
432.49
EC Number:
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

assay

≥98% (TLC)

form

powder

optical activity

[α]25/D -5.4°, c = 4.9 in 1 M HCl(lit.)

color

white to off-white

mp

202-203 °C (lit.)

solubility

H2O: soluble
ethanol: soluble

ε (extinction coefficient)

8,700 at 294 nm at 1 M

originator

Merck & Co., Inc., Kenilworth, NJ, U.S.

SMILES string

[H]\C(=C(/[H])C(O)=O)C(O)=O.CC(C)(C)NC[C@H](O)COc1nsnc1N2CCOCC2

InChI

1S/C13H24N4O3S.C4H4O4/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17;5-3(6)1-2-4(7)8/h10,14,18H,4-9H2,1-3H3;1-2H,(H,5,6)(H,7,8)/b;2-1-/t10-;/m0./s1

InChI key

WLRMANUAADYWEA-NWASOUNVSA-N

Gene Information

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Application

Timolol maleate has been used as an adrenergic β-blocker for evaluating cardiovascular functions in mice5. It has also been used for evaluating the uptake of 86Rb+ in rat cardiomyocytes6.

Biochem/physiol Actions

Timolol maleate is a class II anti-arrhythmic agent that functions as a non-selective β-adrenoceptor antagonist, a vasodilator and an anti-glaucoma agent. Studies have reported that timolol maleate can be used for the treatment of infantile hemangioma (IH)7.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Timolol maleate is soluble in ethanol and water.

pictograms

Health hazardExclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral - Repr. 2

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

ppe

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges


Osvědčení o analýze (COA)

Vyhledejte osvědčení Osvědčení o analýze (COA) zadáním čísla šarže/dávky těchto produktů. Čísla šarže a dávky lze nalézt na štítku produktu za slovy „Lot“ nebo „Batch“.

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Verena Prokosch et al.
PloS one, 8(2), e49730-e49730 (2013-03-08)
Optic nerve atrophy caused by abnormal intraocular pressure (IOP) remains the most common cause of irreversible loss of vision worldwide. The aim of this study was to determine whether topically applied IOP-lowering eye drugs affect retinal ganglion cells (RGCs) and
Ajith Chakkittakandiyil et al.
Pediatric dermatology, 29(1), 28-31 (2011-12-14)
Therapeutic options for superficial infantile hemangiomas (IH) are limited. Recently, timolol maleate gel, a topical nonselective beta-blocker, has been reported as a potentially effective treatment for superficial IH. This study is an extension of a previously published pilot study designed
G C Chiou et al.
Journal of ocular pharmacology, 8(3), 183-190 (1992-01-01)
An ocular hypertensive rabbit eye model was used to study the effect of L- and D-timolol on retinal and choroidal blood flow. Ocular hypertension was induced artificially by raising the intraocular pressure to 40 mmHg which reduced the ocular blood
M Gallarate et al.
International journal of pharmaceutics, 440(2), 126-134 (2012-10-20)
After an initial screening of ingredients and production methods, nanoemulsions for ocular administration of timolol containing the drug as maleate (TM) or as ion-pair with AOT (TM/AOT) were prepared. The physico-chemical characterization of nanoemulsions, regarding mean diameter, pH, zeta potential
Hsien Chan et al.
Pediatrics, 131(6), e1739-e1747 (2013-05-08)
Timolol maleate 0.5% gel is a safe and effective medication for treating superficial infantile hemangiomas (IHs) in infants with a median age of 9 weeks. Forty-one infants who had superficial IHs without ulceration and not near mucosal surfaces were recruited

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.